Clinical trials: Immunoglobulin
Recurrent or Metastatic Head and Neck Carcinoma
Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a single-center, open-label phase 2 study evaluating sacituzumab tirumotecan in combination with an immune checkpoint inhibitor in patients with previously treated recurrent or metastatic head and neck squamous cell…
- Trial name
- NCT07686588
- Testing
- Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor
- Volunteers
- 20 people
- Sponsor
- Biying Chen
Allosensitization, Heart Transplant Failure and Rejection
Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation
The purpose of this study is to test whether daratumumab, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting heart transplantation.
- Trial name
- NCT04088903
- Testing
- Daratumumab
- Sponsor
- Ronald Witteles
Dog Bite
Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in Children
To determine Immunogenicity and Safety Study of Modified TRC-ID Regimen with A New Chromatographically Purified Vero Cell Rabies Vaccine (SPEEDA®) as post exposure rabies intradermal regimen with or without Rabies Immunoglobulin…
- Trial name
- NCT02339896
- Testing
- rabies vaccine
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Relapsed/Refractory Aggressive B-Cell Lymphoma
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810).
- Trial name
- CLIO-1 (NCT02651662)
- Testing
- cemiplimab, odronextamab
- Where
- 30 sites in United States, Austria and 4 more
- Volunteers
- 105 people
- Sponsor
- Regeneron Pharmaceuticals
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
The purpose of this study is to see if ficlatuzumab when combined with cytarabine, a standard treatment for AML, is safe to give to patients and to determine the best dose to give.
- Conditions
- Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT02109627
- Testing
- Ficlatuzumab, Cytarabine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- C. Babis Andreadis
Schizophrenia, Psychosis
Study of Immunotherapy in Autoantibody Positive Psychosis
Psychosis is a mental health problem that causes people to perceive or interpret things differently from those around them, often involving hallucinations or delusions.
- Conditions
- Schizophrenia, Psychosis, Auto Immune Disorders
- Trial name
- SINAPPS-1 (NCT02449746)
- Testing
- Plasma Exchange, Intravenous immunoglobulin
- Where
- 5 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- University of Cambridge
Systemic Vasculitis
Acquired Immunodeficiency in ANCA Associated Vasculitis
This study will address the following hypothesis: Rituximab therapy leads to an acquired immune deficiency, as demonstrated by impaired vaccine responses, in AAV patients. Aims: 1.
- Trial name
- ACQUIVAS (NCT03514979)
- Testing
- Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination
- Where
- United Kingdom
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Hypertriglyceridemia
A First in Human Study of STT-5058, an Antibody That Binds ApoC3
A First in Human Study of STT-5058, an Antibody That Binds ApoC3, investigating single and multiple ascending intravenous doses and ascending subcutaneous doses of STT-5058 in otherwise healthy volunteers with elevated…
- Trial name
- NCT04419688
- Testing
- STT-5058
- Where
- United Kingdom
- Volunteers
- 93 people
- Sponsor
- Staten Biotechnology BV
Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell…
- Trial name
- NCT06736418
- Testing
- 225Ac-ABD147
- Where
- 12 sites in United States
- Volunteers
- 17 people
- Sponsor
- Abdera Therapeutics Inc.
Myositis, Myasthenia Gravis
Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis
The traditional treatment of inflammatory myopathies (IM) and generalized myasthenia gravis (MG) is immunosuppressive therapy, usually beginning with corticosteroids.
- Trial name
- FORCE (NCT00774462)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bronchial Asthma
Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma Subjects, with Dosing Every 12 or 24 Weeks for 48 Weeks
- Trial name
- NCT07054034
- Testing
- MG-ZG122 Humanized Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Neuroblastoma
Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00002634
- Testing
- filgrastim, monoclonal antibody 3F8, cisplatin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diabetic Macular Edema (DME)
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO
- Trial name
- ALTO (NCT07734844)
- Testing
- Tabirafusp tedromer, Aflibercept (2.0 mg)
- Where
- 9 sites in United States
- Volunteers
- 910 people
- Sponsor
- Kodiak Sciences Inc
Advanced Lung Cancer
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
This is an open-label phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab and with or without standard chemotherapy in patients with…
- Trial name
- NCT05664971
- Testing
- Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection, Toripalimab, Docetaxel
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced Breast Cancer, Metastatic Breast Cancer
A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
The primary objective of Phase II is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2-positive, unresectable locally advanced or metastatic breast cancer.
- Trial name
- NCT04924699
- Testing
- MRG002, Trastuzumab Emtansine for Injection
- Where
- 19 sites in China
- Volunteers
- 350 people
- Sponsor
- Shanghai Miracogen Inc.
AQP4+ NMOSD
A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
The goal of this clinical trial is to find out if the investigational medicine BMS-986353 is safe and well tolerated in adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- NCT07573332
- Testing
- CC-97540 (BMS-986353), Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Texas Southwestern Medical Center
Myasthenic Crisis, Myasthenia Gravis (MG)
Efficacy of IVIG Versus PLEX in Myasthenic Crisis in Syria.
This study compares the clinical effectiveness of Intravenous Immunoglobulin (IVIG) versus Plasma Exchange (PLEX) in patients experiencing a myasthenic crisis.
- Trial name
- NCT07532707
- Testing
- IVIG (Intravenous Immunoglobulin), Plasma exchange (PE)
- Where
- Syria
- Volunteers
- 50 people
- Sponsor
- Damascus University
Glioblastoma
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
Glioblastomas are the most common and most aggressive primary brain tumors in adults. The prognosis is poor despite multimodal therapy with surgery, radiotherapy and chemotherapy. Therefore, novel treatments are urgently needed.
- Trial name
- GLIOSTAR (NCT04573192)
- Testing
- L19TNF, Lomustine
- Where
- 15 sites in France, Germany and 2 more
- Volunteers
- 142 people
- Sponsor
- Philogen S.p.A.
Paroxysmal Nocturnal Hemoglobinuria
Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria
The purpose of this study was to determine whether LFG316 can induce a hematological response, as measured by reduction in hemolytic activity, in patients with paroxysmal nocturnal hemoglobinuria (PNH).
- Trial name
- NCT02534909
- Testing
- LFG316, LNP023
- Where
- 7 sites in Czechia, Japan and 1 more
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).
- Trial name
- NCT06749899
- Testing
- QL1706, Gemcitabine, Cisplatin
- Where
- 19 sites in China
- Volunteers
- 580 people
- Sponsor
- Sun Yat-Sen University Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.